Form 4: Can-Fite BioPharma: Motti Farbstein Reports Option Grant

Motti Farbstein, CEO, CFO, and COO of Can-Fite BioPharma Ltd., reported the acquisition of 24,000 stock options with an exercise price of $2.04.

Summary

• Motti Farbstein, who holds executive positions as CEO, CFO, and COO at Can-Fite BioPharma Ltd., has reported a transaction related to his beneficial ownership of the company's securities.
• The transaction involves the acquisition of 24,000 stock options.
• These options have an exercise price of $2.04 per share, which is equivalent to NIS 5.94 based on an exchange rate of NIS 2.908 = USD 1.00 as of June 5, 2026.
• The options are subject to vesting conditions, with sixteen equal quarterly installments beginning September 4, 2026, and concluding on April 6, 2030, contingent upon continued service.
• Following this transaction, Farbstein beneficially owns 33,132 ordinary shares directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral, as it solely reports an option grant to an executive without providing any financial performance or strategic updates that would significantly impact the company's valuation.

Positives

• Motti Farbstein, a key executive, has been granted stock options, indicating potential alignment of management interests with shareholder value.
• The stock options have a defined exercise price, providing a clear benchmark for potential future gains.
• The vesting schedule over several years suggests a commitment to long-term performance and retention.

Negatives

• The filing only reports an option grant and does not provide financial performance data or strategic updates, limiting the scope of positive interpretation.
• The value of the options is contingent on future stock price performance and continued employment.

Risks

• The value of the stock options is directly tied to the future performance of Can-Fite BioPharma's stock price, which is subject to market volatility and company-specific risks.
• Vesting of the options is contingent on the reporting person's continued service, meaning any departure before vesting would result in forfeiture.
• The exercise price of $2.04 requires the stock price to increase significantly for the options to be profitable.

Future Outlook

The filing does not contain forward-looking statements or guidance regarding the company's financial performance or strategic direction. It solely reports a stock option grant to an executive.

Industry Context

StockSavvy.ai notes that the grant of stock options to key executives like Motti Farbstein is a common practice in the biopharmaceutical industry to incentivize performance and align executive interests with those of shareholders, especially in companies focused on long-term drug development and commercialization.

Stakeholder Impact

• Shareholders: The grant of options to a key executive may be viewed positively as it aligns management incentives with potential future stock price appreciation. However, the dilutive effect of future share issuance upon exercise should be considered.
• Employees: The vesting schedule for options is tied to continued service, reinforcing employee retention efforts.
• Management: Motti Farbstein benefits from the potential for future financial gain through the exercise of these options, contingent on company performance and continued employment.

Next Steps

• Vesting of stock options will occur in sixteen equal quarterly installments starting September 4, 2026, and ending April 6, 2030, subject to continued employment.
• The options are exercisable until June 4, 2036.

Key Dates

Keywords

Can-Fite BioPharma, CANF, Motti Farbstein, stock options, beneficial ownership, SEC Form 4, insider trading, executive compensation, biopharmaceutical